Drug
PLN-74809 (Bexotegrast)
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
PLN-74809, is an oral once daily antifibrotic being studied for the treatment of idiopathic pulmonary fibrosis (IPF). PLN-74809 inhibits integrins αVβ1 and αVβ6, which in turn blocks activation of TGF-β, a central mediator of fibrosis. This upstream inhibition of TGF-β activation may prevent the formation of fibrotic tissue within the lung.
Study Purpose
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Find a Clinical Trial